



A 8505-C cells

Treatment	IC50 of Doxorubicin (nM)	Fold Change	% of Fold Change
Scrambled siRNA + DMSO	98.61 ± 2.41	1.00 ± 0.02	Reference
Scrambled siRNA + RAD001	54.45 ± 5.65	0.52 ± 0.06	48 % ↓
Atg-5 siRNA #1 + RAD001	92.58 ± 6.44	0.94 ± 0.07	6 % ↓
Atg-5 siRNA #2 + RAD001	94.91 ± 5.38	0.96 ± 0.05	4 % ↓




B TPC-1 cells


Treatment	IC50 of Doxorubicin (nM)	Fold Change	% of Fold Change
Scrambled siRNA + DMSO	52.97 ± 3.72	1.00 ± 0.07	Reference
Scrambled siRNA + RAD001	32.75 ± 2.63	0.62 ± 0.05	38 % ↓
Atg-5 siRNA #1 + RAD001	48.42 ± 1.58	0.91 ± 0.03	9 % ↓
Atg-5 siRNA #2 + RAD001	49.41 ± 1.02	0.93 ± 0.02	7 % ↓





A





B



A




B



A 8505-C cells

Treatment	IC50 of Doxorubicin (nM)	Fold Change	% of Fold Change
DMSO	104.34 ± 12.46	1.00 ± 0.12	Reference
RAD001	51.52 ± 2.62	0.49 ± 0.03	51 % ↓
PHA665752	54.70 ± 6.96	0.52 ± 0.07	48 % ↓
RAD001 + PHA665752	49.17 ± 1.44	0.47 ± 0.01	53 % ↓



B TPC-1 cells

Treatment	IC50 of Doxorubicin (nM)	Fold Change	% of Fold Change
DMSO	51.99 ± 4.09	1.00 ± 0.08	Reference
RAD001	31.92 ± 2.90	0.61 ± 0.06	39 % ↓
PHA665752	32.22 ± 3.38	0.62 ± 0.06	38 % ↓
RAD001 + PHA665752	25.45 ± 1.08	0.49 ± 0.02	51 % ↓

